Vaccination Coverage among Prisoners: A Systematic Review

Nancy Vicente-Alcalde 1, Esther Ruescas-Escolano 2, Zitta Barrella Harboe 3,4 and José Tuells 4,5,*

1 Penitentiary Center Alicante II, Carretera N-330, Km. 66, 03400 Villena, Spain; nanvical@gmail.com
2 Servicio de Urgencias, Hospital Universitario del Vinalopó-Elche, Calle Tonico Sansano Mora, 03293 Elche, Spain; esther.ruescas@gmail.com
3 Department of Pulmonary and Infectious Diseases, University Hospital of Copenhagen, North Zealand Dyrehavevej 29, 3400 Hillerød, Denmark; Zitta.barrella.harboe@regionh.dk
4 European Society of Clinical Microbiology and Infectious Diseases, Vaccine Study Group—EVASG, 4010 Basel, Switzerland
5 Department of Community Nursing, Preventive Medicine and Public Health and History of Science, University of Alicante, San Vicente del Raspeig, 03690 Alicante, Spain

* Correspondence: tuells@ua.es

Received: 30 August 2020; Accepted: 14 October 2020; Published: 19 October 2020

Abstract: Prison inmates are highly susceptible for several infectious diseases, including vaccine-preventable diseases. We conducted a systematic international literature review on vaccination coverage against hepatitis B virus (HBV), hepatitis A virus (HAV), combined HAV/HBV, tetanus-diphtheria, influenza, pneumococcal, and combined measles, mumps, and rubella (MMR) in prison inmates, according to the PRISMA guidelines. The electronic databases were used Web of Science, MEDLINE, Scopus, and Cinhal. No language or time limit were applied to the search. We defined vaccination coverage as the proportion of vaccinated prisoners. There were no limitations in the search strategy regarding time period or language. Of 1079 identified studies, 28 studies were included in the review. In total, 21 reported on HBV vaccine coverage (range between 16–82%); three on HAV (range between 91–96%); two studies on combined HAV/HBV (77% in the second dose and 58% in the third); three studies on influenza vaccine (range between 36–46%), one of pneumococcal vaccine coverage (12%), and one on MMR coverage (74%). We found that data on vaccination coverage in prison inmates are scarce, heterogeneous, and do not include all relevant vaccines for this group. Current published literature indicate that prison inmates are under-immunized, particularly against HBV, influenza, MMR, and pneumococci. Strengthen immunization programs specifically for this population at risk and improvement of data record systems may contribute to better health care in prisoners.

Keywords: prisoners; inmates; vaccination coverage; immunization programs

1. Introduction

Today, there are more than 11 million prison inmates around the world [1]. Prison inmates are at higher risk of acquiring communicable diseases compared to the background population [2]. This increased risk is not only related to factors such as overcrowding and high turnover rates of prisoners, but also to factors inherent to the inmates, such as higher proportions of individuals with high-risk behaviors including injecting drug use, sexual risk, and higher prevalence of communicable diseases among others [3,4].

Many prevalent communicable diseases in prisons can be prevented by vaccination. Even though several of these vaccines should be administered as a part of routine national immunization programs
during early childhood, factors such as social marginalization, migration, and coming from areas with poor access to health care may contribute to a lower immunization rates, with a higher number of individuals susceptible to vaccine-preventable diseases in prisons around the world [3].

The higher prevalence of communicable diseases among prison inmates may contribute as well to the risk of infectious diseases in the general population since prisoners are often released after short periods of incarceration back into society [5–7]. On the other hand, prison inmates belong often to what are considered hard-to-reach populations (e.g., injecting drug users (IDUs), illegal migrants, and sex workers), who may often be reluctant to participate in public health programs [8,9]. Thus, the period of imprisonment can be considered as an opportunity for relevant public health interventions that is often underutilized [10].

Several international health authorities and organizations including the World Health Organization [11], the European Centers for Disease Control [12], and the Centers for Disease Control and Prevention [13] provide a framework with recommendations for the vaccination of prison inmates. A recent review in prisons settings evaluates the acceptance and cost-effectiveness of vaccines, although it is limited in European countries [14].

However, local implementation of these recommendations largely varies across countries; while high-income countries might have specific vaccination guidelines for this group [15–18], these may be absent or precarious in less industrialized countries. Furthermore, general recommendations may not be very applicable to the reality of prisons in resource-limited settings [4].

Estimates of vaccine coverage are one of the main tools that can be used to indirectly estimate the level of immunity against diseases in any given population. Vaccine coverage estimates also reflect the level of adherence to recommendations for immunization and allow us to tailor preventive interventions according to the specific immunization gaps in the population. In this systematic review, we aimed to identify studies on vaccination coverage against several vaccine-preventable diseases in prison inmates and thus identify areas for possible public health interventions.

2. Materials and Methods

A systematic review of the international literature was carried out following the PRISMA methodology to compile the existing evidence on vaccination coverage in prisons at international level.

The literature search by two reviewers was performed on 20 February 2020 in the electronic databases Web of Science, MEDLINE, Scopus, and Cinhal. The search keywords that were used were: vaccines, vaccination coverage, immunization programs, prisons, prisoners, and inmates in jail. In the search string, the operators “OR” and “AND” were used when relevant, obtaining the following search string: (((((((“Vaccines”[Mesh]) OR “Vaccines”[Title/Abstract])) OR ((vaccination Coverage[MeSH Terms]) OR vaccination Coverage[Title/Abstract]))) OR ((Immunization Programs[MeSH Terms]) OR Immunization Programs[Title/Abstract]))) AND (((((“Prisons”[Title/Abstract]) OR Prisons[MeSH Terms])) OR ((prisoners[MeSH Terms]) OR prisoners[Title/Abstract])))) OR “inmate”[Title/Abstract]) OR “jail”[Title/Abstract]) AND Humans[Mesh]). No language or time limit were applied to the search.

The following steps were carried out in the bibliographic search: analysis of the documents with extraction of the most relevant information; synthesis of the information that was ordered, combined and evaluated in a comparative way; finally, the end of the search, where we obtained the selected articles included in the review (Figure 1).

The articles were selected through the screening of titles, abstracts and by reading the full text articles, based on predefined inclusion and exclusion criteria based on the PICO (patient, intervention, comparison, outcome) model. Prisoners were defined as any person admitted to prisons. Correctional facilities were defined as jails or prisons and custodial settings that function as prisons, excluding immigrant centers and police detection rooms. The intervention included any strategy that provided data on HIV status and vaccination against communicable diseases upon entry and during prison stay (including outbreak situations). The researchers considered
studies with data from community settings, those comparing the inmate population and community settings, those that compared inmates with each other, and those that compared between different risk groups. The following items were considered: people reached by a certain intervention, people who have completed the vaccination, people with serological status, and vaccination coverage. Vaccination coverage was defined as the proportion of prisoners who receive the vaccines recommended by the prison health authorities of their country.

Figure 1. Flowchart selection process (PRISMA).

The selected articles had to provide the vaccination coverage of the prisoners regardless of the vaccine studied. Systematic reviews, articles that did not study vaccines, those that did not provide data on vaccination coverage, and those carried out outside the prison setting were excluded.

All search and selection steps were performed by three independent researchers (NVA, ERE, ZBH) and the results were compared and discussed between the three. All selected registries (including articles that raised doubts) were verified by an investigator with experience in the field of vaccine research (JT). The outline of the review can be seen in Figure 1.

Data from selected studies were extracted into tables designed by one investigator and reviewed by a second investigator. The tables contained information on the characteristics of the study: author, year of publication, country (ISO 3166-2), type of study, vaccine studied, methodology for obtaining results (serology, questionnaire, database), type of vaccination carried out (systematic, update of the vaccination program, vaccination of risk groups, or upon admission to prison), vaccination regimen used during the study, study sample, and vaccination coverage.

3. Results

Of a total of 1079 results obtained in the four databases consulted, 475 articles were excluded because of duplicates. Subsequently, the remaining 604 articles were reviewed, 576 of which were excluded when applying the inclusion and exclusion criteria, resulting in a final sample of 28 articles (Table 1).
Table 1. Characteristics of included studies.

| Author                     | Year | Country | Design        | Vaccine         | Metodology | Target Group | Vaccination Schedule                                                                 | Sample  | Coverage  |
|-----------------------------|------|---------|---------------|-----------------|------------|--------------|---------------------------------------------------------------------------------------|---------|-----------|
| Costumbrado J. et al. [19]  | 2012 | US      | Cross-sectional | Hepatitis A+B   | N          | S            | 0, 7, 21–30 days, 12 months booster                                                   | 1633 inmates (M) | Dose 2: 77% |
| Getaz L. et al. [20]        | 2016 | CH      | Cross-sectional | Hepatitis A     | SA         | A-RG         | single dose                                                                           | 116 inmates (NR) | 96%       |
| Bayas J.M. et al. [21]      | 1993 | ES      | Cross-sectional | Hepatitis B     | SA         | S            | 0 months, 15 days–3 months, 6–12 months                                              | 705 inmates (M)  | Dose 1: 31% |
| Clarke J. et al. [22]       | 2003 | US      | Cross-sectional | Hepatitis B     | N          | S            | NR                                                                                   | 236 inmates (F)  | Dose 1: 67% |
| Christensen P.B. et al. [23]| 2004 | DK/EE   | Open label extension | Hepatitis B   | SA         | RG           | schedule 1: 0, 1, 3 weeks schedule 2: 0 months, 1 months, 6 months                  | 72 DK 566 EE (M/F) | DK: schedule 1: 63% |
| Devine A. et al. [24]       | 2007 | AU      | Cross-sectional | Hepatitis B     | SA         | S-A          | 0 months, 1 months, 6 months                                                         | 204 inmates (F)  | Dose 1: 83% |
| Jacomet C. et al. [25]      | 2015 | FR      | Cross-sectional | Hepatitis B     | SA         | S            | NR                                                                                   | 357 inmates (M)  | Dose 1: 23% |
| Rotily M. et al. [26]       | 1997 | FR      | Cross-sectional | Hepatitis B     | SA-QS      | S            | 0 months, 1 months, 2 months                                                         | 391 inmates (M/F) | Dose 1: 96% |
| Gilbert R.L. et al. [27]    | 2004 | UK      | Cross-sectional | Hepatitis B     | D          | S            | >18 years 0, 7, 21 days, 12 months <18 years 0, 1, 2 months, 12 months              | 42 prisons (M/F) | Average rate 17% |
| Plugge E.H. et al. [28]     | 2007 | UK      | Cross-sectional | Hepatitis B     | QS         | S            | NA                                                                                   | 613 inmates (F)  | 27.3%     |
| Gilles M. et al. [29]       | 2008 | AU      | Cross-sectional | Hepatitis B     | D          | S            | NR                                                                                   | 185 inmates (M)  | Hepatitis B 79% |
| Beck CR. et al. [30]        | 2012 | UK      | Retrospective ecological | Hepatitis B   | D          | S            | NR                                                                                   | 9173 inmates (M/F) | 22%       |
| Gidding HF. et al. [31]     | 2015 | AU      | Cross-sectional | Hepatitis B     | QS-SA      | S            | 0 months, 1 months, 2 months 12 months booster                                    | 531 inmates (M/F) | Males: 24.1% |
| Perrodeau F. et al. [32]    | 2016 | FR      | Cross-sectional | Hepatitis B     | D          | S            | 2 doses                                                                               | 231 inmates (M/F) | 63%       |
| Taylor JEB. et al. [33]     | 2019 | UK      | Cross-sectional | Hepatitis B     | QS         | S            | NR                                                                                   | 346 inmates (M/F) | 52.30%    |
| Perrett S.E. et al. [34]    | 2019 | UK      | Cross-sectional | Hepatitis B     | D          | S            | 0 months, 1 months, 3 months 12 months booster                                     | 3560 inmates (M)  | 2013 28.7%  |

Int. J. Environ. Res. Public Health 2020, 17, 7589
Table 1. Cont.

| Author                  | Year | Country | Design         | Vaccine     | Metodology | Target Group | Vaccination Schedule | Sample                      | Coverage       |
|-------------------------|------|---------|----------------|-------------|------------|--------------|----------------------|-----------------------------|----------------|
| Stasi C. et al. [35]    | 2019 | IT      | Prospective study | Hepatitis B | SA         | S-A          | 0, 7, 21 days, 12 months | 1075 inmates (M)             | 82.60%         |
| Removille N. et al. [36]| 2011 | LU      | Cross-sectional  | Hepatitis A+B | QS-SA      | S-RG         | NR                   | 368 inmates (M)              |                |
| Gilbert R.L. et al. [37]| 2004 | UK      | Cross-sectional  | Hepatitis A  | QS         | S-A          | single dose          | 1563 inmates (M)             | 91%            |
| Nijhawan A.E et al. [38] | 2010 | US      | Cross-sectional  | Hepatitis A+B | QS         | S            | NR                   | 100 inmates (F)              | 47%            |
| Robinson S. et al. [39] | 2012 | US      | Cross-sectional  | Influenza    | N          | S            | single dose          | Centre A 802 inmates (M)     |                |
| Seib K. et al. [40]    | 2013 | US      | Cross-sectional  | Influenza    | QS         | S            | single dose          | 25 correctional inmates (NR) | Seasonal 70% |
| Walkty A. et al. [41]  | 2011 | CA      | Cross-sectional  | MMR          | N          | S            | single dose          | 135 inmates (M)              | 42% inmates  |
| Awofeso N. et al. [42] | 2001 | AU      | Cross-sectional  | Hepatitis B  | SA         | RG           | 0 months, 1 months, 2 months | 1037 inmates (M)             | 1 cohort 85% |
| Sutton A.J. et al. [43] | 2006 | UK      | Model-based      | Hepatitis B  | N          | A-RG         | NR                   | 11,393 inmates (M/F)        | 1998: 27% 2004: 59% |
| Hope V.D. et al. [44]  | 2007 | UK      | Prospective survey | Hepatitis B | SA         | RG           | NR                   | 285 inmates (M/F)            | Glasgow prisoners, Scotland prisoners (M/F) |
| Palmateer N.E et al. [45]| 2018 | UK      | Cross-sectional  | Hepatitis B  | SA         | RG           | 0 month, 1 month, 2 months booster | Glasgow prisoners, Scotland prisoners (M/F) |
| Winter R. et al. [46]  | 2016 | AU      | Cross-sectional  | Hepatitis B  | SA         | A            | NR                   | 285 inmates (M/F)            | 25%            |

QS: Quest Survey, SA: Serological analysis, D: Database, N: Nothing, S: Systematic/program update, RG: Risk group (IDUs, HIV, HCV), A: Admission. Admission to prison, M: Male, F: Female, NR: no report.
The United Kingdom is the country from which most studies on vaccination coverage in prisoners were retrieved (n = 9) [27,28,30,33,37,41,44,45], followed by the United States (n = 5) [19,22,38–40], Australia (n = 5) [24,29,31,42,46] and France (n = 3) [25,26,32]. To a lesser extent, with one article from each country, we found Spain [21], Italy [35], Luxembourg [36], Canada [41], Switzerland [20], and Denmark [23].

We found the following vaccines and vaccine-preventable diseases studied: hepatitis B virus (HBV), hepatitis A virus (HAV), combined HAV/HBV, influenza, pneumococcal, and combined measles, mumps, and rubella (MMR) vaccines.

The methods used to investigate the vaccination status of the inmates were: serological testing (n = 10) [20,21,23–25,35,42,44,46], the use of questionnaires (n = 5) [28,33,37,38,40], the combination of both (n = 3) [26,31,36], the screening of institutional databases (n = 5) [27,29,30,32,34], or directly by conducting a survey (n = 5) [19,22,39,41,43].

The aim of the studies was to evaluate systematic vaccination or relevant update of the adult vaccination program (n = 21) [19,21,22,24–41], to explore the coverage of risk groups (n = 7) [20,23,36,42–45], including in some studies vaccination status at the time of admission to prison (n = 6) [20,24,35,37,43,46]. The risk groups studied were IDUs and hepatitis C positive (HCV) in the HBV studies [23,42–45], and men who have sex with men in a combined HAV/HBV immunization study [19] and in another HAV immunization study [20]. In 11 studies (39.2%), exclusively men were included [19,21,25,29,34–37,41,42], in 4 studies (14.2%) only women were included [22,24,28,38], in 11 articles (39.2%) both sexes [23,26,27,30–33,43–46] and in 2 (7.1%) these data were not recorded [20,40]. The most studied vaccination coverage was HBV (n = 21) [21–36,42–46] followed by influenza (n = 3) [10,29,39], HAV (n = 3) [20,36,37], combined HAV/HBV vaccine (n = 2) [19,38], pneumococcal (n = 1) [29] and MMR (n = 1) [41].

Among the 21 studies that focused on HBV vaccine, five studies detailed the reasons why prisoners were not vaccinated [21–25]. As shown in Table 1, most of the studies sought to update HBV vaccination programs to achieve improvements in vaccination coverage [21,22,25–34]. The vaccination schedules used were different, most commonly at 0 (entry point), 1 month, 2 months, and a booster between 6–12 months. The vaccination coverage obtained ranged between 16% [24] and 82.6% [35].

The three studies that provided data on HAV vaccination coverage in prisons are European [20,36,37]. One study was carried out in the United Kingdom as a result of a community outbreak of HAV and included 1363 prisoners in a mass vaccination program and reached a vaccination coverage of 91% [37]. In this study, a similar vaccine coverage (91%) was seen among IDUs [37]. Another study carried out in Luxembourg among 368 prisoners, showed a higher vaccination coverage in non-IDUs (65.9%) than in IDUs (57.1%) [36]. The Swiss study in 2016 included 116 prisoners (52% of African origin) who underwent serological testing that demonstrated immunity in 96% of them [20]. In this study, the authors only recommend HAV vaccination for risk-groups and not routinely for all prisoners.

Two of the studies in our systematic reviewed explored the HAV/HBV combination vaccine [20,38]. The study from Costumbrado et al. [19] published in 2012 focused on a rapid vaccination program in 1633 prisoners (schedule at 0, 7, 21–30 days, and boosted at 12 months) with Twinrix®, in men who have sex with men. The coverage achieved was 77% for the second dose, 58% for the third and 11% for the fourth. In the same study, they offered HBV vaccination with the traditional schedule (at 0–1 month and 4–6 months) to all prisoners, with a coverage of 59% for the second dose and 22% for the third dose. The study from Nijhawan et al. [38] published in 2010, carried out on 100 female prisoners in the US, indicated a vaccination coverage for HAV/HBV combined of 47% obtained through surveys.

Gilles and colleagues [29] assessed the coverage of public health interventions in 185 Australian male and female prisoners by accessing local databases. They author found that even though 52% of inmates had at least one chronic disease and an indication for immunization, vaccination coverage for influenza was only 36%, pneumococcal vaccine coverage 12%, and HBV 79%. Robinson et al. [39] studied influenza vaccination in the context of an influenza outbreak identified in two prisons, which led
to a mass vaccination campaign of all prisoners. The campaign achieved a vaccination coverage of 42–46% in prisoners and 25–37% in staff. Seib et al. [40] carried out a study using a questionnaire to evaluate vaccination strategies in 25 prisons; they provided data on the vaccination coverage of seasonal influenza of 70% and H1N1 of 64%.

There is only one study reporting on mumps in prisoners in the context of an outbreak in Canada in 2011, in which the MMR vaccine was offered to the entire inmate population. They campaign achieved 83% of vaccination coverage in prisoners and 36% in staff [41].

4. Discussion

Vaccination coverage in prison inmates has been a subject of limited interest. Most studies deal with HBV and its direct relationship with a risk group (IDUs or HCV positive inmates) [42–44]. In 2016, the World Health Assembly set as a goal eliminating viral hepatitis by 2030, including a 95% reduction in new HBV infections through improved vaccine coverage [47]. The CDC recommends HBV vaccination in prison inmates, considering this population as a high-risk group. The need to achieve adequate HBV immunization levels in high risk populations (e.g., HCV and HIV positive individuals, and IDUs) is widely recognized; however, of the 28 studies included, there were only data from these groups in seven of them. Despite its efficacy and wide availability, HBV vaccine coverage varies substantially by geographic region and prison category, even in high-income countries [30].

Eight studies from the United Kingdom on HBV vaccination coverage have been published, and despite policy changes favoring vaccination in prisons in the 1990s, no major advances have been observed in vaccine coverage [27]. In 2001, new actions were initiated that offered the vaccine against HBV in a limited number of prisons, to all prisoners upon arrival through an accelerated program (0, 1 and 3 weeks, with a booster at 12 months). Since the introduction of this intervention, vaccine coverage has increased: in 2003, the mean HBV vaccine coverage in prisons in England and Wales was 17% [27]; this increased to 22% in 2010 [30]. Perret et al. published data from 2013 where they found coverage of 28.7% and 39.6% in 2017, documenting differences in trends by the type of prison [34].

Regarding the type of interventions, accelerated HBV vaccination programs improved compliance and may contribute to achieve higher immunization rates, particularly for the high proportion of inmates serving short sentences [10,21,23,32,35]. In line with this finding, Palmateer et al. described an association between a higher vaccination coverage in inmates who were imprisoned more than once [45].

The main reasons associated with non-vaccination when carrying out an intervention program in prisons were the release before the administration of the vaccine, previous or current infection, having previously received the vaccine, and refusal to vaccination [21–25,33]. In the Italian study published by Stasi et al., being a foreigner was a risk factor associated with not being vaccinated [35], and in the publication by Taylor et al., the most common reason for not being vaccinated was that inmates never had been offered the vaccine or that they never came to complete the guidelines once they started [33].

In this review, a limited number of studies on vaccination coverage of HAV, influenza, pneumococcal, and MMR in prisoners were identified and none on diphtheria-tetanus or BCG were included, similarly to what was published in the review by Madeddu et al. [14] in 2019, focused on vaccination in prisoners of the European Union/European Economic Area. Even though HAV vaccination of inmates is not routinely recommended by the CDC, vaccination of certain risk groups including, among others, individuals with underlying chronic liver diseases, HBV, HCV, and HIV infected individuals, pregnancy, men who have sex with men, and homeless people, all conditions that may be present among inmates [20,37]. HAV immunity in the study by Getaz et al. was high (96%), but likely related to the development immunity during childhood in the regions of origin of inmates. Targeted vaccination according to the area of origin and risk factors for complications (such as chronic liver disease) would improve the immunity of this group and protect vulnerable populations at risk of exposure in this precarious environment in cases of an outbreak of HAV [20].
Few published studies on combined HAV/HBV vaccination were conducted in the US. In a recent review by Madeddu et al. [14] in 2019, there were five studies on this vaccine that were also including cost-effectiveness.

Regarding influenza, current guidelines recommend offering seasonal influenza vaccine to high-risk groups in the general population, including the elderly and chronically ill, and do not refer to incarcerated persons specifically [48]; except for the Australian study in 2008 [29], which is a study focusing on influenza vaccination in the post-2009 H1N1 pandemic. In the publication by Seib et al. [40] the importance of immunizations in prisons is highlighted given the greater rates of transmission. Despite the experience from the 2009 H1N1 pandemic, influenza vaccines are not routinely administered to prisoners with risk factors, but in contrast initiated in the context of outbreaks.

The only published study on MMR vaccine coverage summarizes the general conclusions of the other studies included in the review: data on vaccine coverage in prisoners are scarce, state vaccination registries are not usually available to verify the vaccination status of prisoners, and inmates are an accessible risk-group [41]. To this should be added the lack of human resources to administer vaccines, especially in emergencies or outbreaks [40].

The most common vaccination modality in a prison is the systematic approach, either as a primary vaccination, as booster or as a post-exposure dose, although massive vaccination programs are also used to control outbreaks. We must remember that, similarly to the general population, acceptance of vaccination is voluntary.

Despite international guidelines and the publication of many evidence-based interventions that demonstrate benefit, a huge gap remains in the introduction and expansion of vaccination programs in prisons in both low- and high-income countries. Cooperation and coordination between the penitentiary and public health systems is necessary to guarantee equity in access to prevention services for the population during incarceration [7].

The extreme sociodemographic heterogeneity of the prisoners, influenced by migration, makes it difficult to assume that the vaccination coverage of this specific population resembles to what otherwise found in the general population at any given time. Carrying out an intervention in closed populations with a large proportion of susceptible individuals exposed to a high risk of contagion, such as the prison community, allows obtaining optimal vaccination coverage and better results compared to vaccination carried out in the general population. This represents an opportunity to approach groups that, under normal conditions, have little contact with the health system. Therefore, it is of special interest to have data on vaccination coverage in prisons in order to prioritize interventions or reinforce vaccination schedules according to the intrinsic risk of each prison; reach as many susceptible people as possible by avoiding vaccinating people who have already been vaccinated or who have already suffered from the disease.

The limitations of the study are mainly those derived from the heterogeneous methodology of the selected studies, since vaccine coverage data are not the main objective of some of them and interpretation of the data was made. This may at least in part explain some discrepancies in the results, when compared to the review by Madeddu et al. [14] Likewise, the heterogeneity in vaccination policies, when they exist, makes studies from different geographical locations not very comparable due to the intrinsic characteristics of each area.

All studies were carried out in industrialized countries, leaving major gaps in the available knowledge we have from prisons in developing countries.

5. Conclusions

Prisoners are often an ignored and neglected population regarding public health policies at the international level. Harmonization of recommendations of vaccination strategies in prisons could be a fundamental step to improve access to health care, and for minimizing economic, organizational and disease burden in this setting.
Vaccination strategies varied between countries and were often either targeting a specific vaccine-preventable disease or being implemented as part of an outbreak response. However, subsequent evaluations of the implemented interventions were not carried out systematically or are simply missing. Thus, these approaches may seem arbitrary and we were not able to evaluate whether specific interventions could have contributed to improve vaccination coverage and the overall health conditions of prisoners.

Author Contributions: Conceptualization, J.T. and N.V.-A.; methodology, J.T. and N.V.-A.; software, N.V.-A.; validation, N.V.-A., E.R.-E., and Z.B.H.; formal analysis, N.V.-A., E.R.-E.; investigation, N.V.-A., E.R.-E., and J.T.; data curation, N.V.-A., E.R.-E.; writing—original draft preparation, N.V.-A., E.R.-E. and J.T.; writing—review and editing, N.V.-A., E.R.-E., Z.B.H., and J.T. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. The World Prison Brief. Available online: https://www.prisonstudies.org (accessed on 1 July 2020).
2. European Centre for Disease Prevention and Control. Systematic Review on Hepatitis B and C Prevalence in the EU/EEA; European Centre for Disease Prevention and Control: Stockholm, Sweden, 2016.
3. European Centre for Disease Prevention and Control; European Monitoring Centre for Drugs and Drug Addiction. Public Health Guidance on Prevention and Control of Blood-Borne Viruses in Prison Settings; ECDC: Stockholm, Sweden; EMCDDA: Stockholm, Sweden, 2018.
4. Bick, J.A. Infection Control in Jails and Prisons. Clin. Infect. Dis. 2007, 45, 1047–1055. [CrossRef]
5. Aebi, M.; Chopin, J.; Tiago, M.M.; Burkardt, C. SPACE I—C; Council of Europe: Strasbourg, France, 2018; Available online: http://wp.unil.ch/wp.unil.ch/space/space-i/prison-stock-on-1st-january/2018-2/ (accessed on 13 May 2020).
6. World Health Organization. Health in Prisons: Fact Sheets for 38 European Countries. Available online: https://www.euro.who.int/en/health-topics/health-determinants/prisons-and-health/publications/2019/health-in-prisons-fact-sheets-for-38-european-countries-2019 (accessed on 26 May 2020).
7. Kamarulzaman, A.; Reid, S.E.; Schwitters, A.; Wiessing, L.; El-Bassel, N.; Dolan, K.A.; Moazen, B.; Wirtz, A.L.; Verster, A.; Altice, F.L. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet 2016, 388, 1115–1126. [CrossRef]
8. Dolan, K.; Wirtz, A.L.; Moazen, B.; Ndeffo-mbah, M.; Galvani, A.; Kinner, S.A.; Courtney, R.; McKee, M.; Amon, J.J.; Maher, L.; et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016, 388, 1089–1102. [CrossRef]
9. Butler, T.; Simpson, M. National Prison Entrants’ Blood-Borne Virus Survey Report 2004, 2007, 2010, 2013, and 2016; University of NSW: Sydney, Australia; The Kirby Institute: Sydney, Australia, 2017.
10. Li, H.; Cameron, B.; Douglas, D.; Stapleton, S.; Cheguelman, G.; Butler, T.; Luciani, F.; Lloyd, A.R. Incident hepatitis B virus infection and immunisation uptake in Australian prison inmates. Vaccine 2020, 38, 3255–3260. [CrossRef] [PubMed]
11. World Health Organization. Prisons and Health; World Health Organization: Geneva, Switzerland, 2014.
12. ECDC. Immunisation 2016. Available online: http://ecdc.europa.eu/en/healthtopics/immunisation/pages/index.aspx (accessed on 28 May 2020).
13. Mast, E.E.; Weinbaum, C.M.; Fiore, A.E.; Alter, M.J.; Bell, B.P.; Finelli, L.; Rodewald, L.E.; Douglas, J.M.; Janssen, R.S.; Ward, J.W. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: Immunization of adults. MMWR Mortal Morb Wkly. Rep. Recomm Rep. 2006, 55, 1–33.
14. Madeddu, G.; Vroling, H.; Oordt-Speets, A.; Babudieri, S.; O’Moore, É.; Noordegraaf, M.V.; Monarca, R.; Lopalco, P.L.; Hedrich, D.; Tavoschi, L. Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high-income countries. Vaccine 2019, 37, 4906–4919. [CrossRef] [PubMed]
15. National Institute for Health and Care Excellence. Physical Health of People in Prison; National Institute for Health and Care Excellence: London, UK, 2016.
16. Health Protection Agency and Department of Health—Offender Health. Prevention of Communicable Disease and Infection Control in Prisons and Places of Detention. A Manual for Healthcare Workers and Other Staff; Health Protection Agency: London, UK, 2011.
17. Società italiana di Malattie Infettive e Tropicali. Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1; Società Italiana di Malattie Infettive e Tropicali: Prato, Italy, 2016.
18. Grupo de Trabajo Vacunación en Población Adulta y Grupos de Riesgo de la Ponencia de Programa y Registro de Vacunaciones. Vacunación en Grupos de Riesgo de Todas las Edades y en Determinadas Situaciones; Comisión de Salud Pública del Consejo Interterritorial del Sistema Nacional de Salud; Ministerio de Sanidad, Consumo y Bienestar Social: Madrid, Spain, 2018.
19. Costumbrado, J.; Stirland, A.; Cox, G.; El-Amin, A.N.; Miranda, A.; Carter, A.; Malek, M. Implementation of a hepatitis A/B vaccination program using an accelerated schedule among high-risk inmates, Los Angeles County Jail, 2007–2010. Vaccine 2012, 30, 6878–6882. [CrossRef] [PubMed]
20. Getaz, L.; Casillas, A.; Motamed, S.; Gaspoz, J.M.; Chappuis, F.; Wolf, H. Hepatitis A immunity and region-of-origin in a Swiss prison. Int. J. Prison. Health 2016, 12, 98–105. [CrossRef]
21. Bayas, J.M.; Bruguera, M.; Martin, V.; Vidal, J.; Rodes, J.; Salleras, L.Y. Hepatitis B vaccination in prisons: The Catalonian experience. Vaccine 1993, 11, 1441–1444. [CrossRef]
22. Clarke, J.; Schwartzapfel, B.; Pomposelli, J.; Allen, S.; Spaulding, A.; Rich, J.D. Hepatitis B vaccination of incarcerated women: A pilot program. J. Health Care Poor Underserved 2003, 14, 318–323. [CrossRef]
23. Christensen, K.; Georgsen, J. Hepatitis B vaccination uptake in prisons across England and Wales 2003–2010: A retrospective ecological study. Vaccine 2012, 30, 549–553. [CrossRef] [PubMed]
24. Devine, A.; Karvelas, M.; Sundararajan, V. Evaluation of a prison-based hepatitis B immunisation pilot project. Aust. N. Z. J. Public Health 2007, 31, 127–130. [CrossRef] [PubMed]
25. Jacomet, C.; Guyot-Lénat, A.; Bonny, C.; Henquell, C.; Rude, M.; Dydymski, S.; Lesturgeon, J.A.; Lambert, C.; Pereira, B.; Schmidt, J. Addressing the challenges of chronic viral infections and addiction in prisons: The PRODEPIST study. Eur. J. Public Health 2016, 26, 122–128. [CrossRef] [PubMed]
26. Gilbert, R.L.; Costella, A.; Piper, M.; Gill, O.N. Increasing hepatitis B vaccine coverage in prisons in England and Wales. Commun. Dis. Public Health 2004, 7, 306–311. [CrossRef]
27. Plugge, E.H.; Yudkin, P.L.; Douglas, N. Predictors of hepatitis B vaccination in women prisoners in two prisons in England. J. Public Health 2007, 29, 429–433. [CrossRef]
28. Gilles, M.; Swingler, E.; Craven, C.; Larson, A. Prison health and public health responses at a regional prison in Western Australia. Aust. N. Z. J. Public Health 2008, 32, 549–553. [CrossRef]
29. Beck, C.R.; Cloke, R.; O’Moore, É.; Puleston, R. Hepatitis B vaccination coverage and uptake in prisons across England and Wales 2003–2010: A retrospective ecological study. Vaccine 2012, 30, 1965–1971. [CrossRef]
30. Gidding, H.F.; Mahajan, D.; Reekie, J.; Lloyd, A.R.; Dwyer, D.E.; Butler, T. Hepatitis B immunity in Australia: A comparison of national and prisoner population serosurveys. Epidemiol. Infect. 2015, 143, 2813–2821. [CrossRef]
31. Perrett, S.E.; Cottrell, S.; Shankar, A.G. Hepatitis B vaccine coverage in short and long stay prisons in Wales, UK 2013–2017 and the impact of the global vaccine shortage. Vaccine 2019, 37, 4872–4876. [CrossRef]
35. Stasi, C.; Monnini, M.; Cellesi, V.; Salvadori, M.; Marri, D.; Ameglio, M.; Gabbuti, A.; Di Fiandra, T.; Voller, F.; Silvestri, C. Screening for hepatitis B virus and accelerated vaccination schedule in prison: A pilot multicenter study. *Vaccine* 2019, 37, 1412–1417. [CrossRef] [PubMed]

36. Removille, N.; Origer, A.; Couffignal, S.; Vaillant, M.; Schmit, J.C.; Lair, M.L. A hepatitis A, B, C and HIV prevalence and risk factor study in ever injecting and non-injecting drug users in Luxembourg associated with HAV and HBV immunisations. *BMC Public Health* 2011, 11, 351. [CrossRef] [PubMed]

37. Gilbert, R.L.; O’Connor, T.; Mathew, S.; Allen, K.; Piper, M.; Gill, O.N. Hepatitis A vaccination—a prison-based solution for a community-based outbreak? *Commun. Dis. Public Health* 2004, 7, 289–293.

38. Nijhawan, A.E.; Salloway, R.; Nunn, A.S.; Poshkus, M.; Clarke, J.G. Preventive healthcare for underserved women: Results of a prison survey. *J. Women’s Health* 2010, 19, 17–22. [CrossRef] [PubMed]

39. Robinson, H.F.; Centers for Disease Control and Prevention (CDC). Influenza outbreaks at two correctional facilities—Maine, March 2011. *MMWR. Morb. Mort. Wkly. Rep.* 2012, 61, 229–232.

40. Seib, K.; Gleason, C.; Richards, J.L.; Chamberlain, A.; Andrews, T.; Watson, L.; Whitney, E.; Hinman, A.R.; Omer, S.B. Partners in immunization: 2010 survey examining differences among H1N1 vaccine providers in Washington state. *Public Health Rep.* 2013, 128, 198–211. [CrossRef]

41. Walkty, A.; Van Caeseele, P.; Hilderman, T.; Buchan, S.; Weiss, E.; Sloane, M.; Fatoye, B. Mumps in prison: Description of an outbreak in Manitoba, Canada. *Can. J. Public Health* 2011, 102, 341–344. [CrossRef]

42. Awofeso, N.; Levy, M.; Harper, S.; Jones, M.; Hayes, M.; Douglas, J.; Fisher, M.; Folpp, D. Response to HBV vaccine in relation to vaccine dose and anti-HCV positivity: A New South Wales correctional facilities’ study. *Vaccine* 2001, 19, 4245–4248. [CrossRef]

43. Sutton, A.J.; Gay, N.J.; Edmunds, W.J. Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales. *Vaccine* 2006, 24, 2577–2386. [CrossRef] [PubMed]

44. Hope, V.D.; Ncube, F.; Hickman, M.; Judd, A.; Parry, J.V. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: Is the prison vaccination programme driving recent improvements? *J. Viral Hepat.* 2007, 14, 653–660. [CrossRef]

45. Palmateer, N.E.; Goldberg, D.J.; Munro, A.; Taylor, A.; Yeung, A.; Wallace, A.; Mitchell, A.; Shepherd, S.J.; Gunson, R.N.; Aitken, C.; et al. Association between universal hepatitis B prison vaccination, vaccine uptake and hepatitis B infection among people who inject drugs. *Addiction* 2017, 113, 80–90. [CrossRef] [PubMed]

46. Winter, R.J.; White, B.; Kinner, S.A.; Stoove, M.; Guy, R.; Hellard, M.E. A nurse-led intervention improved blood-borne virus testing and vaccination in Victorian prisons. *Aust. N. Z. J. Public Health* 2016, 40, 592–594. [CrossRef] [PubMed]

47. World Health Organisation. Global Health Sector Strategy on Viral Hepatitis 2016–2021. 2016. Available online: https://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/ (accessed on 3 March 2020).

48. WHO Fact Sheet. Seasonal Influenza. Available online: http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed on 14 July 2020).

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).